CDH2 and cancer: In majority of epithelial cancers, loss of E-cadherin (CDH1), P-cadherin (CDH3) or both during tumour progression results in an increased expression of the mesenchymal cadherin, i.e. N-cadherin, with a significant change in the adhesive properties of cancer cells, as they lose their affinity for epithelial neighbours in favour of stromal cells [5, 11–15].